# A Study of IBI306 in Participants With Hypercholesterolemia

Study · id `cardio:ct-nct04709536` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04709536](<https://clinicaltrials.gov/study/NCT04709536>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04709536

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 306 participants.

## Technical summary

Registry record NCT04709536. Randomized; triple masking; primary purpose treatment. Start 2021-02-09 (actual); primary completion 2021-11-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 306 participants (enrolled count; ClinicalTrials.gov record NCT04709536, source copy `cardio:ctgov-nct04709536-2024-10-31`, retrieved 2026-10-31)
- Started: 2021-02-09 (actual) (ClinicalTrials.gov record NCT04709536, source copy `cardio:ctgov-nct04709536-2024-10-31`, retrieved 2026-10-31)
- Primary completion: 2021-11-09 (actual) (ClinicalTrials.gov record NCT04709536, source copy `cardio:ctgov-nct04709536-2024-10-31`, retrieved 2026-10-31)
- Completion: 2022-01-28 (actual) (ClinicalTrials.gov record NCT04709536, source copy `cardio:ctgov-nct04709536-2024-10-31`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04709536, source copy `cardio:ctgov-nct04709536-2024-10-31`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04709536-2024-10-31`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of IBI306 in Participants With Hypercholesterolemia
- Condition: Hypercholesterolemia
- Intervention (Drug): IBI306
- Intervention (Drug): Placebo
- Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Innovent Biologics (Suzhou) Co. Ltd. (`cardio:org-innovent-biologics-suzhou-co-ltd`)

## Provenance

Content hash: 32a673d7b89c25b1ebcd6181dfeaf4e6f8ebaa4c7d90297eff43a04595bf14d5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
